The company's strategic focus on product innovation, sales force expansion, operational efficiency, and market penetration has enabled it to maintain a strong competitive position and deliver steady growth. The company reported net revenues of $54.72 million for fiscal 2024 with strong momentum continuing into 2025, demonstrating 18-19% year-over-year growth.
Cyborg Score Rationale
Electromed has demonstrated consistent financial growth and profitability in recent years with a net profit margin of 9.4%. The company benefits from a niche market position with growing awareness of HFCWO therapy, though it faces regulatory and competitive challenges in the broader respiratory device sector.
Top Insights
Strong momentum with 18.9% revenue growth in H1 FY2025, driven by 16.7% homecare growth and 25.5% hospital revenue growth.
SmartVest Connect wireless technology enables data-driven collaboration between physicians and patients for optimized therapy performance.
Established pioneer in HFCWO technology since 1992, with SmartVest becoming the standard of care for chronic respiratory conditions.
Increasing awareness of the benefits of HFCWO therapy continues to drive industry growth.
Named Competitors
Hill-Rom Vest — Competing HFCWO airway clearance system
Respirtech InCourage — Alternative high-frequency chest compression device
Percussion-Matic — Percussion-based airway clearance system
Recent Developments
(February 2026) Reported record Q2 2026 revenue and profitability with EPS of 32 cents
(February 2026) Received Buy rating from Lake Street analyst
(December 2024) Achieved 18.9% revenue growth in H1 FY2025 with strong hospital and homecare segment performance
Open the full interactive Electromed, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.